

## INTISARI

Pandemi COVID-19 akibat SARS-CoV-2 masih terus terjadi hingga hari ini. Data per 19 November 2021 total 255,3 juta jiwa di seluruh dunia terkonfirmasi positif COVID-19 dan 5,1 juta jiwa di antaranya meninggal dunia. Terapi plasma konvalesen (TPK) digunakan sebagai terapi suportif untuk pasien COVID-19 dengan status EUA (*Emergency Use Authorization*) yang dikeluarkan oleh US-FDA (The United State of Food and Drug Administration). Penelitian bertujuan untuk mengevaluasi luaran klinis pasien COVID-19 rawat inap yang mendapatkan TPK di Rumah Sakit Akademik (RSA) UGM Yogyakarta selama periode bulan Januari–Agustus 2021.

Penelitian merupakan observasional analitik menggunakan desain *cross sectional* secara retrospektif dengan pengumpulan data melalui rekam medis pasien. Luaran klinis dievaluasi melalui jumlah pasien pulang dan meninggal, lama rawat inap, dan parameter laboratorium. Faktor yang diduga berpengaruh terhadap luaran klinis berupa status akhir, yaitu tingkat perbaikan dan kematian juga dianalisis. Data yang didapatkan akan dianalisis secara deskriptif.

Pasien yang didapatkan pada penelitian ini total sebanyak 146 pasien, 100 diantaranya masuk kriteria inklusi dengan karakteristik paling banyak berjenis kelamin laki-laki, usia  $\geq 60$  tahun, golongan darah B dan O, mempunyai komorbid DM, dan derajat keparahan yang berat. Luaran klinis pasien COVID-19 rawat inap yang mendapatkan TPK memiliki jumlah pasien membaik (62%) lebih tinggi dibandingkan pasien meninggal (38%) terutama pada derajat sedang dan berat, serta lama rawat inap menurun. Parameter inflamasi dan koagulasi kebanyakan masih belum mencapai nilai referensi yang diharapkan, sehingga terapi lain seperti antivirus, antibiotik, antiinflamasi, dan antikoagulan juga digunakan. Melihat hasil penelitian ini, secara keseluruhan plasma konvalesen menghasilkan luaran klinis yang baik pada pasien dengan derajat keparahan sedang atau berat, tetapi tidak pada derajat keparahan kritis.

Kata Kunci: luaran klinis, faktor yang mempengaruhi, terapi plasma konvalesen (TPK), COVID-19

## ABSTRACT

*The COVID-19 pandemic due to SARS-CoV-2 is still happening today. Data per 19<sup>th</sup> of November, 2021, a total of 255,3 million people worldwide were confirmed positive for COVID-19 and 5,1 million of them died. Convalescent Plasma Therapy (CPT) is used as supportive therapy for COVID-19 patients with EUA (Emergency Use Authorization) status issued by the US-FDA (The United State of Food and Drug Administration). This study aims to evaluate the clinical outcomes of hospitalized COVID-19 patients who get CPT at Academic Hospital of Gadjah Mada University, Yogyakarta during the period January-August 2021.*

*The study was an analytic observational study using a retrospective cross-sectional design with data collection through the patient's medical records. The clinical outcomes were evaluated through the number of patients discharged and died, length of stay, and laboratory parameters. A description of the factors that influence the clinical outcome based on final status of the patient was also carried out. The data obtained will be analyzed descriptively.*

*The total number of patients in this study was 146 patients, and 100 patients included the inclusion criteria with the most characteristics male,  $\geq 60$  years old, blood types B and O, comorbid DM, and severe illness. The clinical outcome of hospitalized COVID-19 patients who received CPT administration number patients discharged at good condition was (62%) which was higher than the number of patients died (38%) especially in moderate and severe severity degree, and the length of stay decreased. Most of inflammatory and coagulation parameters have not reached reference values, so other therapies such as antiviral, antibiotic, anti-inflammatory, and anticoagulant are also used. Looking at the result of this study, overall convalescent plasma produced good clinical outcomes in patients with moderate or severe severity, but not at critical level.*

*Keywords: clinical outcomes, influence factors, convalescent plasma therapy (CPT), COVID-19*